Keyphrases
Serum Adiponectin
100%
COPD Outcomes
100%
Hazard Ratio
62%
Adiponectin
37%
Hospitalization
25%
Smoking Status
25%
Mortality Hazard
25%
Bronchial Reactivity
25%
Cardiovascular Mortality
12%
Moderate to Severe
12%
Airflow Limitation
12%
Health Outcomes
12%
Coronary Artery Disease
12%
High Risk
12%
Health Studies
12%
Cardiovascular Outcomes
12%
Cardiovascular Disease
12%
Smokers
12%
Cardiovascular Risk
12%
Lung Health
12%
Serum Samples
12%
Cardiovascular Morbidity
12%
Anti-inflammatory Activity
12%
Serum Biomarkers
12%
Chronic Inflammatory Diseases
12%
Cancer Mortality
12%
Cox Proportional Hazards Model
12%
Total Mortality
12%
Decreased Risk
12%
Decline in Lung Function
12%
Lung Function Tests
12%
Respiratory Mortality
12%
Anti-atherogenic Activity
12%
Accelerated Decline
12%
Respiratory Causes
12%
Antidiabetic Activity
12%
Measurement Reactivity
12%
Material Influence
12%
Multiple Regression Method
12%
Promising Biomarkers
12%
Medicine and Dentistry
Chronic Obstructive Pulmonary Disease
100%
Adiponectin
100%
Hazard Ratio
45%
Cardiovascular System
27%
Lung
27%
Biological Marker
18%
Bronchus Reactivity
18%
Malignant Neoplasm
9%
Cardiovascular Disease
9%
Health Outcomes
9%
Ischemic Heart Disease
9%
Airflow
9%
Proportional Hazards Model
9%
Inflammatory Disorder
9%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Obstructive Lung Disease
100%
Adiponectin
100%
Biological Marker
18%
Malignant Neoplasm
9%
Ischemic Heart Disease
9%
Cardiovascular Disease
9%
Diseases
9%
Immunology and Microbiology
Adiponectin
100%
Bronchus Reactivity
18%
Inflammatory Disorder
9%
Airflow
9%
Biochemistry, Genetics and Molecular Biology
Adiponectin
100%
Bronchus Reactivity
18%
Airflow
9%